Teva Pharmaceutical Industries Ltd (TEVA) Receives Average Recommendation of “Hold” from Brokerages
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has been assigned an average recommendation of “Hold” from the thirty-three analysts that are presently covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $19.50.
A number of equities analysts have recently commented on the stock. Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, February 15th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 13th. Credit Suisse Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $20.00 to $23.00 in a report on Sunday, February 11th. Finally, Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a report on Friday, February 9th.
Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.21 during mid-day trading on Wednesday, reaching $19.37. 3,951,391 shares of the company’s stock were exchanged, compared to its average volume of 18,515,664. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $34.51. The firm has a market capitalization of $19,660.00, a PE ratio of -1.12, a P/E/G ratio of 1.66 and a beta of 0.65.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the sale, the executive vice president now directly owns 44,517 shares in the company, valued at approximately $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.10% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 16.9% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,983 shares of the company’s stock worth $871,000 after purchasing an additional 6,642 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $243,000. Meitav Dash Investments Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $5,017,000. MetLife Investment Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $1,335,000. Finally, Hoylecohen LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $954,000. Institutional investors own 57.31% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.